DE19975064I1 - Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testfahren. - Google Patents

Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testfahren.

Info

Publication number
DE19975064I1
DE19975064I1 DE1999175064 DE19975064C DE19975064I1 DE 19975064 I1 DE19975064 I1 DE 19975064I1 DE 1999175064 DE1999175064 DE 1999175064 DE 19975064 C DE19975064 C DE 19975064C DE 19975064 I1 DE19975064 I1 DE 19975064I1
Authority
DE
Germany
Prior art keywords
necrosis factor
tumor necrosis
dna
preparation
assaying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE1999175064
Other languages
English (en)
Other versions
DE19975064I2 (de
Inventor
Bharat Bhushan Aggarwal
Sang He Lee
David Vannorman Goeddel
Glenn Evan Nedwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/677,257 external-priority patent/US4650674A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE19975064I1 publication Critical patent/DE19975064I1/de
Application granted granted Critical
Publication of DE19975064I2 publication Critical patent/DE19975064I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE1999175064 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren. Active DE19975064I2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62795984A 1984-07-05 1984-07-05
US62805984A 1984-07-05 1984-07-05
US62806084A 1984-07-05 1984-07-05
US67715684A 1984-12-03 1984-12-03
US67745484A 1984-12-03 1984-12-03
US06/677,257 US4650674A (en) 1984-07-05 1984-12-03 Synergistic cytotoxic composition

Publications (2)

Publication Number Publication Date
DE19975064I1 true DE19975064I1 (de) 2005-09-29
DE19975064I2 DE19975064I2 (de) 2005-11-03

Family

ID=27560190

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1999175064 Active DE19975064I2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren.
DE3587939T Expired - Lifetime DE3587939T2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3587939T Expired - Lifetime DE3587939T2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.

Country Status (20)

Country Link
EP (1) EP0168214B1 (de)
JP (4) JP2557341B2 (de)
AT (1) ATE113295T1 (de)
AU (1) AU599571B2 (de)
BG (1) BG60250B1 (de)
CZ (1) CZ283149B6 (de)
DE (2) DE19975064I2 (de)
DK (2) DK169894B1 (de)
FI (2) FI95472C (de)
GR (1) GR851626B (de)
HU (1) HU209153B (de)
IE (1) IE65426B1 (de)
IL (2) IL105271A (de)
LU (1) LU90456I2 (de)
NL (1) NL990033I2 (de)
NO (1) NO852673L (de)
NZ (1) NZ212632A (de)
PL (1) PL155778B1 (de)
SK (1) SK279897B6 (de)
YU (1) YU47968B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
EP0155549B1 (de) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. DNS den menschlichen Tumornekrosisfaktor kodierend und das menschliche Tumornekronisfaktor-Polypeptid
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE3585690D1 (de) * 1984-12-21 1992-04-23 Biogen Inc Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren.
JPS61155330A (ja) * 1984-12-28 1986-07-15 Denichi Mizuno 蛋白質標品
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
EP0247906B1 (de) * 1986-02-04 1994-12-28 Mizuno, Den'Ichi Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
JPH0817712B2 (ja) * 1986-06-20 1996-02-28 大日本製薬株式会社 新規ヒトｔｎｆポリペプチド変異体
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
PT84869B (pt) * 1986-07-31 1990-11-07 Genentech Inc Metodo para a profilaxia e tratamento de infeccoes por retrovirus e processo para a preparacao de composicoes para esse fim, contendo factor de necrose tumoral
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
DK0491878T3 (da) 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
WO1991013908A1 (en) * 1990-03-12 1991-09-19 Peptide Technology Ltd. Neutrophil stimulating peptides
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
CA2155103A1 (en) * 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
WO1995024501A1 (en) 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
EP2953634B1 (de) 2013-02-07 2021-05-26 The General Hospital Corporation Verfahren zur expansion oder abreicherung von t-regulatorischen zellen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH65623A (de) * 1913-08-02 1914-07-01 Siemens Ag Zeitrelais mit Wechselstrommotor und dessen Drehmoment entgegenwirkender Feder
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS60226816A (ja) * 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (de) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha Physiologisch aktives Polypeptid
JPS60221092A (ja) * 1984-04-18 1985-11-05 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄｎａ
JPS60166696A (ja) * 1984-02-08 1985-08-29 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄνａ
JPS60137292A (ja) * 1983-12-26 1985-07-20 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドの遺伝情報を有するポリデオキシリボ核酸、該ポリデオキシリボ核酸を含む複製可能な組換ｄνａ、該複製可能な組換ｄνａで形質転換された微生物または細胞、新規生理活性ポリペプチド及びその製造方法
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
EP0155549B1 (de) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. DNS den menschlichen Tumornekrosisfaktor kodierend und das menschliche Tumornekronisfaktor-Polypeptid
JPS60232097A (ja) * 1984-04-23 1985-11-18 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子ポリペプチドの製造法
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
JP2515975B2 (ja) * 1985-02-26 1996-07-10 大日本製薬株式会社 抗腫瘍作用を有するポリペプチド

Also Published As

Publication number Publication date
EP0168214A2 (de) 1986-01-15
JPH07291997A (ja) 1995-11-07
NL990033I2 (nl) 2000-11-01
JPH083061A (ja) 1996-01-09
NO852673L (no) 1986-01-06
DE19975064I2 (de) 2005-11-03
DK75694A (da) 1994-06-24
DE3587939D1 (de) 1994-12-01
ATE113295T1 (de) 1994-11-15
DK305885D0 (da) 1985-07-04
FI95472C (fi) 1996-02-12
FI943750A0 (fi) 1994-08-15
NZ212632A (en) 1991-05-28
DK169894B1 (da) 1995-03-27
IE65426B1 (en) 1995-11-01
FI852626A0 (fi) 1985-07-03
FI95472B (fi) 1995-10-31
LU90456I2 (fr) 1999-12-06
DK305885A (da) 1986-03-14
FI98217C (fi) 1997-05-12
HU209153B (en) 1994-03-28
EP0168214A3 (en) 1987-12-16
HUT38125A (en) 1986-04-28
SK506785A3 (en) 1999-05-07
IL105271A (en) 1995-07-31
BG60250B2 (bg) 1994-03-24
FI852626L (fi) 1986-01-06
FI943750A (fi) 1994-08-15
JP2614989B2 (ja) 1997-05-28
JPS6140221A (ja) 1986-02-26
AU599571B2 (en) 1990-07-26
BG60250B1 (bg) 1994-03-24
JPH0928387A (ja) 1997-02-04
CZ283149B6 (cs) 1998-01-14
JP2557341B2 (ja) 1996-11-27
AU4465285A (en) 1986-01-09
DK171418B1 (da) 1996-10-21
CZ506785A3 (en) 1997-07-16
GR851626B (de) 1985-11-26
IE851691L (en) 1986-01-05
YU47968B (sh) 1996-08-13
DE3587939T2 (de) 1995-04-27
PL254399A1 (en) 1986-06-17
YU113285A (en) 1991-04-30
NL990033I1 (nl) 1999-12-01
PL155778B1 (pl) 1992-01-31
IL75717A0 (en) 1985-11-29
IL75717A (en) 1994-11-28
SK279897B6 (sk) 1999-05-07
FI98217B (fi) 1997-01-31
EP0168214B1 (de) 1994-10-26

Similar Documents

Publication Publication Date Title
DE19975064I1 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testfahren.
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
AU2427288A (en) Biological materials, processes for producing biological materials and for using such materials in therapy
ES8800984A1 (es) Un metodo para obtener adn que codifica factor de necrosis de tumores mutante